Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China
Fluidigm's microfluidic technology enables highly scalable and automated workflows for quantitative PCR, gene expression, copy number variation analysis and next-generation sequencing library preparation. Used by researchers around the world to detect somatic and genomic variations from patient samples, this unique technology enables the cost efficiencies, flexibility and proven analytical performance that laboratories need to meet the increasing demands of molecular testing.
"We strongly believe our partnership with
"We are very pleased to partner with Ascendas Genomics to expand our market position in China," said
About Ascendas Genomics
Ascendas Genomics develops genetic solutions for diagnostic markets, provides technical and consulting services to clinical research laboratories, academic institutions and biotechnology companies, and offers immunodiagnostic and molecular diagnostic tests to hospitals and health care centers through its subsidiary company,
About Fluidigm
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and
other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases,
Forward-Looking Statement for
This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding anticipated development of diagnostics products and the potential impact of such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to uncertainties in contractual relationships and international regulated markets, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; competition; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm's products; and risks associated with international operations. Information on
these and additional risks, uncertainties, and other information affecting
Contacts: Ascendas GenomicsSource:Xiao Xiao Manager, Marketing Ascendas Genomics 0760-89965088 xiao.xiao@ascendgene.comFluidigm Michaeline Bunting Senior Director, MarketingFluidigm Corporation 650 737 4190 michaeline.bunting@fluidigm.com
News Provided by Acquire Media